Souhaitez-vous accéder aux communiqués récents ?

JUPITER, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology...

Completed Strategic Leadership and Operational Transformation from R&D to Commercial OperationsRebranded as Dyadic Applied BioSolutions to Reflect Our New Operational PrioritiesFull Redesign of...

JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable...

JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of...

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein...

Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media,...

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient...

JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to...